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Abstract
Thyroid diseases are pathologies that frequently affect pregnant women. The objective was to find out whether the expression of
TSHβX1 splice variant and D2 Thr92Ala polymorphism in the DIO2 gene are associated with thyroid disease in pregnant
women. It was a comparative, prospective clinical, and cross-sectional study. Ninety-two pregnant patients, of which 38 were
normothyroid and 54 had thyroid disease, were included. The expression of the TSHβX1 splice variant was quantified by real-
time PCR and the D2 Thr92Ala (rs225014 CT) polymorphismwas genotyped using TaqMan probes. The TSHβX1 splice variant
was detected in both groups without significant differences in the relative expression. The Tallele was associated with the thyroid
dysfunction (OR = 2.117, p = 0.0339). We confirmed the presence of the predicted TSHβX1, and our results suggest that 92Thr
(rs225017T) allele is a risk factor to thyroid dysfunction in pregnant women.
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Introduction
Thyroid diseases are reported in 5 to 10% of all pregnancies
and are associated with serious complications that can contrib-
ute to perinatal death and adverse obstetric events [1, 2]. In
pregnancy, there is excessive thyroid stimulation [3] due to
physiological changes such as increased thyroid-binding glob-
ulin (TBG), increased degradation of T4 to T3 by the inner
ring of D3 abundantly expressed in the placenta, amnion, and
chorion that generates reverse T3 and the effect of human
chorionic gonadotropin (hCG). By sharing alpha chain with
TSH, hCG generates a false stimulation of receptors
increasing the levels of T3 and T4, doing pregnancy a favor-
able scenario for thyroid dysfunctions [4].
On the other hand, deiodinase 2 (DIO2) is a selenoenzyme
responsible for the deiodination of T4 to T3, which makes it
crucial for the proper functioning of thyroid hormones. D2 is
produced by the DIO2 gene (NC_000014.9), which is located
on chromosome 14 in the long arm position 14q24.3 [5]. A
change of the T allele by C generates an amino acid coding
alanine instead of threonine in position 92, which makes the
protein differ from the canonical structure. In 2017, Wouters
et al. proposed that the presence of the Thr92Ala (rs225014
CT) polymorphism of DIO2 influences enzymatic function
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and its presence is thought to predict a favorable response in a
combination therapy of levothyroxine (LT4) and T3 [6].
Furthermore, the Ala92Ala genotype was reported to be relat-
ed with a reduction in the placental activity of D2, which
could worsen gestational complications [7].
In addition to the above, TSH variants have been proven to
be related with thyroid dysfunction, osteoprotection in pa-
tients with hyperthyroidism (TSH-βv), or with immune pro-
cesses (R55G variant) [8–10]. In this line of knowledge, it has
been predicted by automated computational analysis a Homo
sapiens TSH beta transcript variant X1 (TSHβX1)
(XM_011542065.2) derived from a genomic sequence
(NC_000001.11) using the Gnomon gene prediction method
[11]. The predicted variant belongs to the BioProject:
PRJNA168, related to the GenBank project: PRJNA31257.
The aim of this study was to describe the allele frequency
of the Thr92Ala in pregnant women with or without thyroid




This was a clinical, comparative, prospective, and transversal
study. Pregnant women aged 18–44 years old, attended at the
BMónica Pretelini Sáenz^ Maternal-Perinatal Hospital
(HMPMPS), Health Institute of the State of Mexico (ISEM),
Toluca, Mexico, were invited to participate.
Two groups were conformed: (A) Normothyroid pregnant
women (NT) and (B) patients with a thyroid disease named
hypothyroidism or hyperthyroidism (TD). Patients with other
chronic diseases were excluded and those whose clinical
follow-up was lost or that in the puerperium had to be treated
in the obstetric intensive care unit were eliminated from the
study, besides the samples that were not suitable for genetic
analysis were eliminated too.
Sample Calculation
The sample was calculated with Eq. 1.
n0 ¼




where n0: necessary size of the sample, S: standard devia-
tion, d: difference to find, Z alpha = 1.96, Z beta: 0.482. The
relative units (UR) of gene expression were taken into account
as measures, accepting an alpha risk of 0.05 and a beta risk of
0.2 in a bilateral contrast, obtaining a sample size of 48 sub-
jects per group, to detect an equal or greater difference at 4 RU
with a standard deviation of 7.
Sociodemographic Information
All the participants answered a questionnaire that included
demographic information such as name, age and address, ob-
stetric data (number of pregnancies, deliveries, cesareans, and
abortions), and familiar thyroid disease background. The an-
thropometric and laboratory data (weight, height, body mass
index (BMI), glucose, creatinine, triglycerides, total cholester-
ol, and TSH) from all the patients were obtained from the
clinical files.
Blood Samples
Peripheral blood samples (2 tubes of 5 mL, a total blood tube
with EDTA anticoagulant for the genetic analysis, and a dry
tube for the determination of the hormone TSH) were collect-
ed by venipuncture in the arm. All samples were stored at −
80 °C until the analysis.
TSH Quantification
TSH measurements were performed using the ELISA tech-
nique (diagnostics A) at the Research Laboratory of Ciprés
Grupo Médico S.C. (CGM).
Identification of the D2 Thr92Ala
Polymorphism
DNA Extraction
The DNAwas extracted in the Laboratory of Genetics, Faculty
of Medicine, UAEMex, using the kit QIAmp DNA Mini and
Blood kit fromQiagenDNA, (Cat no./ID: 51106). The genetic
material purity and integrity were measured with the
Nanodrop 1000 and was stored at − 20 °C until genotyping.
DNA integrity was verified by E-Gel gels in the E-Gel iBase
and E-Gel Safe Imager (Invitrogen).
Genotyping
The genotyping was carried out with a total concentration of
30 ng/μl in each reaction well, using 0.06 μl of the rs225014
(Thr92Ala) primers and probes contained in Human Custom
TaqMan Genotyping Assay C__15819951_10, 2.5 μl of
Master Mix, 2.44 μl of water and 5 μl of DNA (all from
Thermo Fisher Scientific, Waltham, MA, USA). Then, a con-
ventional PCR was performed in a GeneAmp System 9700
thermal cycler using the following cycling program: denatur-
ation of: 50 °C 2min, and 95 °C 10min, followed by 40 cycles
of 94 °C 15 s, and 40 cycles 60 °C 1 min; to finish at 4 °C
7 min. At the end of the PCR program, the amplified plate was
taken to the QuantStudio 3 Real-Time PCR System
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genotyping equipment using TaqMan probes to process each
sample of the patients. Genotyping data were validated by
sequencing three samples from each genotype as we previous-
ly reported [12] and using the following primers: 5′




The RNAwas extracted in the Laboratory of Genetics, Faculty
of Medicine, UAEMex, using the Norgen’s Total RNA
Purification Kit (Norgen Biotek Corp.). The purity and integ-
rity of total RNA were assessed using a NanoPhotometer
(Implen GmbH, Germany).
Real-Time PCR
In the Research Laboratory of Ciprés Grupo Médico S.C.
(CGM), the TSHβX1 expression was determined by the real-
time PCR technique in a PrimeQ (Techne, UK) equipment.
The primers used were synthesized at the Synthesis and DNA
Sequencing Unit of the National Autonomous University of
Mexico (UNAM), Institute of Biotechnology (Cuernavaca,
Morelos, Mexico). The SYBR Green RNA to Ct 1 step Kit
(Cat. number 4389986) was used with the following oligonu-
cleotides: GADPH (House keeping gene): 5′CTTGGTAT
CGTGGAAGGACTC 3 ′ , 3 ′GTAGAGGCAGGGAT
GATGTTCT 5′ and TSHβX1: 5′TGTGGGCAAGCGAT
GTCTTTT 3′, 3′GATGGTTAGGCAATAAGCACACT 5′.
The reaction was done with a final volume of 50 μl, the
primers’ concentration were of 200 nM and the samples of
100 ng. Cycling was programmed in the following way:
retrotranscription step (48 °C 30 min × 1 cycle), enzyme acti-
vation (95 °C 10 min × 1 cycle), denaturation (95 °C 15 s × 40
cycles), alignment (59 °C 30 s × 40 cycles), extension (60 °C
30 s × 40 cycles), and melting curve (72 °C 1 min × 61 cy-
cles). The fold change in TSHBX1 splice variant was
normalized against GADPH and then compared with the con-
trols through the 2−ΔΔCT method.
Statistical Analysis
Hardy-Weinberg equilibrium (HWE) was evaluated to the
Thr92Ala genotypes by using Finetti program (https://ihg.
gsf.de/cgi-bin/hw/hwa2.pl). Continuous data were expressed
as means ± standard deviation (SD). Statistical analysis was
performed using the Mann–Whitney U test after performing
the Levene test. The normality hypothesis was tested using the
Kolmogorov–Smirnov test. Odds ratio (OR) test was used to
compare the TSHBX1 splice variant positive identification, D2
Thr92Ala genotypes, and alleles with the presence/absence of
thyroid disease. Statistical significance was tested at the p ≤ 0.
05 level using SPSS ver. 23.0 software (IBM Corp., Armonk,
NY, USA).
Ethics
All participants gave their informed consent and both the
Research Committee and the Ethics on Research Committee
of the HMPMPS approved the protocol (code: 2016-09-481).
All procedures were performed in accordance with the
Declaration of Helsinki and the General Health Law inMexico.
Results
Sociodemographic and Anthropometric Data
Of all the 96 samples collected, four were excluded because
their clinical follow-up was lost; obtaining anN = 92, of which
54 had thyroid dysfunction (cases) and 38 were NT (controls).
The initial proportion of both groups changed because in the
analysis of TSH serum levels, it was found that more patients
had altered hormone through the follow-up period. The de-
scription of the study population is depicted in Table 1.
There were no differences in the number of abortions
among groups, which led to infer that in the patients analyzed,
Table 1 General description of study population
Group Age (years)
mean ± SD




> 1 pregnancies N (%) N (%) N (%)
Control group (N = 38) 27 ± 8 15 (39.47) 23 (60.52) 11 (28.94) 5 (13.15)
Thyroid disfunction
(N = 54)
28 ± 5 22 (40.7) 32 (59.25) 14 (20.37) 19 (35.18)
Total
(N = 92)
28 ± 7 37 (40.21) 55 (59.78) 25 (27.17) 24 (26.08)
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the thyroid pathology was not influencing the gestational
losses. Regarding the relationship of the health status of the
patients with the presence or absence of a family history of
thyroid disease, it was observed that while 86% (n = 33) of the
patients in the NT group had no family history, by contrast,
35.18% (n = 19) of the patients with a thyroid dysfunction had
a family member with a thyroid-related disease. A significant
p < 0.05 was obtained when looking for this relationship,
evidencing that there is a connection between family history
and thyroid dysfunction. The descriptive statistics of the
groups are observed in Table 2.
In terms of BMI, most of the patients belong to the category
of overweight and obesity. However, there was no significant
difference between the two groups. Regarding blood pressure,
only one patient in each study group presented hypertension.
In addition, 13 different dosage types of levothyroxine or
thiamazol were registered and only one patient was untreated.
TSH Screening
Taking into account the reference values for TSH per trimester
[14], seven patients were reassigned to the group of thyroid
diseases because their serum TSH levels exceeded the limits
allowed in the specific gestational trimester.
D2 Thr92Ala Allele Frequency
The genotypes were in HWE, showing the next distribution:
40 (48.2%) patients presented the CC genotype, of which 22
(55%) had no thyroid disease, while 18 (45%) were from the
group with thyroid dysfunction. For the CT genotype, which
was found in 33 (39.8%) patients, the opposite happened that
the majority of the (n = 23, 69.7%) patients with thyroid dys-
function had it and 10 (30.3%) were from the NT group. The
TT genotype was present in 10 (12%) patients who, in their
majority (n = 7, 70%), were patients with thyroid dysfunction.
In summary, the T allele was the most common in cases with
thyroid dysfunction in comparison with NT (OR = 2.117, p =
0.0339) (Table 3). Comparisons between TSH levels and each
genotype were performed without finding significant
differences.
TSHβX1 Expression
This TSHBX1 splice variant was present in 14 (25.92%) of the
cases and in 13 (34.21%) of the controls. Eleven cDNA sam-
ples were not adequate for expression analysis. When
performing the OR analysis between the state of health and
the presence/absence of the gene transcript, there was not con-
firmation of a significant statistical difference (OR 0.6731,
95% CI 0.2722–1.6643, p = 0.3914). Otherwise, the fold
change was of 3.33 in the TD group vs ND group for the
relative expression of this splice variant.
Discussion
The thyroid diseases do not have a unique origin; genetic,
endogenous, and environmental factors are involved [15,
16]. It has been previously published that a relationship be-
tween obesity and hypothyroidism in which leptin levels in-
tervene and in which TSH is directly responsible for weight
gain [17]. Perhaps, a population without these basic problems
would have seen a significant difference between the two
study groups.
Of particular concern is that not suffering a thyroid disease
in pregnancy does not exonerate a healthy patient from having
complications in postpartum due to the thyroid gland. In fact,
Table 2 Anthropometric, clinical
characteristics, and biochemical







Weight (kg) 70.0 (± 14.3) 70.1 (± 14.7) 69.9 (± 14.1)
Height (cm) 155 (± 0.0) 1.55 (± 0.06) 155 (± 0.05)
SBP (mmHg) 108.4 (± 11.8) 109.3 (± 13.4) 107.3 (± 9.5)
DBP (mmHg) 68.3 (± 10.3) 69.2 (± 11.9) 67.2 (± 7.9)
BMI (kg/m2) 28.9 (± 5.0) 29.01 (± 5.3) 28.8 (± 4.6)
Glucose (mg/dL) 80.0 (± 16.0) 79 (± 18) 81.3 (± 13.3)
TC (mg/dL) 205 (± 54.7) 216.3 (± 62.0) 188.5 (± 37.9)
TG (mg/dL) 213.4 (± 94.9) 225.3 (± 105.1) 198.4 (± 80.2)
Hb (g/dL) 13.2 (± 1.5) 12.9 (± 1.7) 13.5 (± 1.1)
Creatinine
(mg/dL)
0.6 (± 0.1) 0.60 (± 0.1) 0.58 (± 0.1)
BMI body mass index, DBP diastolic blood pressure, Hb hemoglobin, SBP systolic blood pressure, TC total
cholesterol, TG triglycerides
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5 to 18% of healthy patients present in the first year a post-
partum thyroiditis [18, 19]. What is clear from this study is the
relationship between the family history of thyroid disease and
the health status of our patients. The previous thing verifies the
great influence of the genetic background in the presentation
of the disease. In this case, there are many genes involved in
the development of these diseases, which can follow a pattern
in terms of anomalies over several generations. In addition,
the most frequent pathology at the thyroid level was clinical
hypothyroidism, which is consistent with the epidemiological
data regarding the incidence of the disease [20].
For instance, DIO2 and TSH have been implicated in
the thyroid disease development. Polymorphisms in
DIO2 could interfere in the expression level or the activ-
ity of this enzyme, potentially altering the metabolism of
thyroid hormones [7, 21]. On this field, comparing the
Thr92Thr homozygous and Thr92Ala heterozygous geno-
types, the D2 activity has been found to decline among
Ala92Ala homozygous [22]. In fact, the D2 Ala92Ala
genotype is related with a reduction in the placental ac-
tivity of D2, which could worsen gestational complica-
tions [7]. Studying pregnant women with or without thy-
roid disease, we identified the Thr92 (T) allele as a risk
factor to thyroid disease in pregnant women. So far, most
of the studies attribute the C allele as the diseased geno-
type since it has been associated with drug resistance,
lower T3 values, and complications with diabetes
[23–25]. However, other group reported the C allele as
more common in healthy patients suggesting that it is a
low-risk factor for the disease [26] which is in accor-
dance with our data. A differential distribution of these
alleles between ethnic groups have been reported, being
the C allele the less frequent in populations with Asian
and European ancestry than subjects with Amerindian
background [27]. These contradictory results have to be
elucidated; however, we cannot discard that sample sizes
and the genetic background could bias our results.
An important issue to take into account is the identifi-
cation of possible risk factors in order to improve the
prevention methods in pregnancies’ complications.
According to the 2017 Guidelines of the American
Thyroid Association (ATA) for the Diagnosis and
Management of Thyroid Disease During Pregnancy and
the Postpartum, if any of the following risk factors are
identified, testing for serum TSH is recommended: (1) a
history of hypothyroidism/hyperthyroidism or current
symptoms/signs of thyroid dysfunction, (2) known thy-
roid antibody positivity or presence of a goiter, (3) history
of head or neck radiation or prior thyroid surgery, (4)
age > 30 years, (5) type 1 diabetes or other autoimmune
disorders, (6) history of pregnancy loss, preterm delivery,
or infertility, (7) multiple prior pregnancies (≥ 2), (8) fam-
ily history of autoimmune thyroid disease or thyroid dys-
function, (9) morbid obesity (BMI ≥ 40 kg/m2), (10) use
of amiodarone or lithium, or recent administration of io-
dinated radiologic contrast, and (11) residing in an area of
known moderate to severe iodine insufficiency [14].
From the above mentioned risk factors, autoimmunity in
our population seems to be one of the most important factors,
since wemust take into account that the percentage of mothers
with AITD and with an affected daughter is 13% [28], but the
challenge we face is to detect this autoimmunity process be-
fore pregnancy. Even more, the results of this survey support
the usefulness of the identification of polymorphisms and ge-
netic variants that increase the risk of developing thyroid dis-
ease during pregnancy.
Our study constitutes a characterization of the Mexican
population and also confirms a role for a strict thyroid
function monitoring during pregnancy [4]. In case of in-
stitutional budget limitations, TSH must be measured in
the first trimester to all pregnant women with a strong
family history of thyroid disease, over 30 years of age,
with autoimmune diseases, morbid obesity, or who have
received radiation in head and neck [29].
Table 3 Genotype and allele
distribution per group Thr92Ala rs225014
CT




OR IC (95%) p
value
Genotype N = 35 N = 48
Ala92Ala (CC) 22 (62.8) 18 (37.5) 0.07
Thr92Ala (TC) 10 (28.6) 23 (47.9)








C 54 (73.3) 59 (61.5)
T 16 (26.7) 37 (38.5) 2.1165
[1.0585–4.2322]
0.0339
99% of genotyping (low DNA quality in one sample)
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Finally, in this initial approach, the higher fold change in
the expression of the TSHβX1 splice variant in the TD group
makes suppose an implication of this variant to develop a
thyroid dysfunction. Notwithstanding, the information is not
conclusive and needs further corroboration.
At this stage, the presence of the TSHβX1 splice var-
iant in the analyzed population opens the possibility of a
new study, in which the role of the interactome in thy-
roid dysfunctions can be evidenced, to see if the associ-
ation of the resulting protein with other molecules is
involved with the disease. In other words, the studies
have to establish if the protein-protein interactions are
affecting the cellular response [30].
Limitations of our study include the relatively low
number of patients, even for our institution, attributed
to the rate of acceptance of the patients to participate
into any study but at the same time, it is valuable to
see ethical recommendations avoiding coercion in such
an important decision. Secondly, the possibility of strat-
ification bias cannot be ruled out in our sample due to
the treatment of the patients. It is also a limitation the
scarce information of the TSHβX1 splice variant thus
restricting the conclusions of its positive expression.
Further, the TSH serum increments in the NT group dur-
ing the following period made us lose the initial equal
distribution of the groups, forcing us to use nonparamet-
ric tests in the analysis.
Conclusions
Our data suggests that the allele T of Ala92Ala is associated
with thyroid disease. To the best of our knowledge, this is the
first study showing expression of the predicted TSHβX1 splice
variant in human pregnant women, being an example of the
certainty of the informatics sequence genome prediction.
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